Jr. Michael Conick Hanley - Feb 17, 2022 Form 4 Insider Report for Aeglea BioTherapeutics, Inc. (AGLE)

Role
Chief Commercial Officer
Signature
/s/ James Kastenmayer, by power of attorney
Stock symbol
AGLE
Transactions as of
Feb 17, 2022
Transactions value $
$0
Form type
4
Date filed
2/22/2022, 03:51 PM
Next filing
Jun 10, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGLE Employee Stock Option (right to buy) Award $0 +160K $0.00 160K Feb 17, 2022 Common Stock 160K $3.17 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 17, 2022, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Remarks:

Exhibit 24 - Power of Attorney